ARS Pharmaceuticals Net Income Over Time
| SPRY Stock | 9.45 0.60 6.78% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ARS Pharmaceuticals Performance and ARS Pharmaceuticals Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ARS Pharmaceuticals. If investors know ARS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive ARS Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.81) | Revenue Per Share | Quarterly Revenue Growth 14.716 | Return On Assets | Return On Equity |
Understanding ARS Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects ARS's accounting equity. The concept of intrinsic value - what ARS Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push ARS Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between ARS Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ARS Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, ARS Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare ARS Pharmaceuticals and related stocks such as GH Research PLC, Nanobiotix, and Arbutus Biopharma Corp Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GHRS | (310 K) | (310 K) | (310 K) | (310 K) | (310 K) | (310 K) | (310 K) | (310 K) | (310 K) | (310 K) | (446 K) | (9.2 M) | (22.5 M) | (35.6 M) | (39 M) | (35.1 M) | (33.3 M) |
| NBTX | (5.2 M) | (5.2 M) | (5.3 M) | (8.1 M) | (9.6 M) | (17 M) | (21.9 M) | (26.1 M) | (29.9 M) | (50.9 M) | (33.6 M) | (47 M) | (57 M) | (39.7 M) | (68.1 M) | (61.3 M) | (58.3 M) |
| ABUS | (8.8 M) | (9.7 M) | 29.9 M | (14.1 M) | (38.8 M) | (61.1 M) | (384.1 M) | (84.4 M) | (57.1 M) | (153.7 M) | (63.7 M) | (76.2 M) | (69.5 M) | (72.8 M) | (69.9 M) | (62.9 M) | (66.1 M) |
| LENZ | (109 K) | (109 K) | (109 K) | (109 K) | (109 K) | (109 K) | (109 K) | (109 K) | (109 K) | (109 K) | (68.4 M) | (70.8 M) | (10.8 M) | (70 M) | (49.8 M) | (44.8 M) | (47 M) |
| SVRA | (3.7 M) | (13.3 M) | (15.6 M) | (21.5 M) | (28.7 M) | (39.8 M) | (10.9 M) | (29.8 M) | (61.5 M) | (78.2 M) | (49.6 M) | (43 M) | (38.1 M) | (54.7 M) | (95.9 M) | (86.3 M) | (82 M) |
| RZLT | (49.3 K) | (49.3 K) | (6.7 M) | (9.7 M) | (11.4 M) | (14.9 M) | (20.3 M) | (29.9 M) | (30.4 M) | (20.3 M) | (20.9 M) | (41.1 M) | (51.8 M) | (68.5 M) | (74.4 M) | (67 M) | (63.6 M) |
| KURA | (33.6 K) | (22.4 K) | (27 K) | (27.3 K) | (11 M) | (22.6 M) | (27.6 M) | (35.4 M) | (60.4 M) | (63.1 M) | (89.6 M) | (130.5 M) | (135.8 M) | (152.6 M) | (174 M) | (156.6 M) | (148.8 M) |
| PROK | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (26.7 M) | (55.1 M) | (108 M) | (35.5 M) | (61.2 M) | (70.4 M) | (73.9 M) |
| PVLA | 66.2 K | 66.2 K | 66.2 K | 66.2 K | (9.8 M) | (14.1 M) | (22.8 M) | (17.6 M) | (26.8 M) | (25.5 M) | (37.2 M) | (45.7 M) | (33.3 M) | 18.7 M | (17.4 M) | (15.7 M) | (16.5 M) |
| TYRA | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (9.3 M) | (26.1 M) | (51.7 M) | (69.1 M) | (86.5 M) | (77.8 M) | (73.9 M) |
ARS Pharmaceuticals and related stocks such as GH Research PLC, Nanobiotix, and Arbutus Biopharma Corp Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in ARS Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of ARS Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| ARS Pharmaceuticals | SPRY |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 11682 El Camino |
| Exchange | NASDAQ Exchange |
null 9.45
Additional Tools for ARS Stock Analysis
When running ARS Pharmaceuticals' price analysis, check to measure ARS Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARS Pharmaceuticals is operating at the current time. Most of ARS Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ARS Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARS Pharmaceuticals' price. Additionally, you may evaluate how the addition of ARS Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.